A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Auch Frankreich hatte mit neun Goldmedaillen sehr erfolgreich abgeschnitten. Deutschland folgte deutlich dahinter mit vier Titeln. Russland und die Niederlande hatten jeweils drei Europameister in ihren Reihen, wobei Russland mit insgesamt 21 Medaillen deutlich mehr Edelmetall gesammelt hatte als die Niederlande, die auf insgesamt 6 Medaillen kam. Mit Polen, der Ukraine, Spanien, Italien und Belarus gab es weitere fünf Nationen mit jeweils zwei Europameistern in ihren Reihen. Dabei lag Polen mit insgesamt zwölf Medaillen vor der Ukraine – acht Medaillen gesamt, Spanien – sechs Medaillen gesamt, Italien – drei Medaillen gesamt – und Belarus – zwei Medaillen gesamt. Bei den einzelnen Sportlern sind besonders folgende Leistungen zu nennen.
Vier Athleten errangen je zwei Goldmedaillen bei diesen Meisterschaften: Mo Farah (Großbritannien) – 5000 Meter, 10.000 Meter Dafne Schippers (Niederlande) – 100 Meter und 200 Meter Adam Gemili (Großbritannien) – 200 Meter und 4-mal 100 Meter Martyn Rooney (Großbritannien) – 400 Meter und 4-mal 400 Meter Folgende Europameister von 2014 hatten bereits vorher EM-Titel gewonnen: Mo Farah (Großbritannien) – 5000 Meter, dritter Titel in Folge, außerdem über 10.000 Meter Wiederholung seines Erfolgs von 2010, damit jetzt fünffacher Europameister Renaud Lavillenie (Frankreich) – Stabhochsprung, dritter Titel in Folge Olha Saladucha (Ukraine) – Dreisprung, dritter Titel in Folge Sandra Perković (Kroatien) – Diskuswurf, dritter Titel in Folge Adam Kszczot (Polen) – 800 Meter, Wiederholung seines Erfolgs von 2012 Sergei Schubenkow (Russland) – 110 Meter Hürden, Wiederholung seines Erfolgs von 2012 David Storl (Deutschland) – Kugelstoßen, Wiederholung seines Erfolgs von 2012 Robert Harting (Deutschland) – Diskuswurf, Wiederholung seines Erfolgs von 2012 Krisztián Pars (Ungarn) – Hammerwurf, Wiederholung seines Erfolgs von 2012 Ruth Beitia (Spanien) – Hochsprung, Wiederholung ihres Erfolgs von 2012 Éloyse Lesueur (Frankreich) – Weitsprung, Wiederholung ihres Erfolgs von 2012 Anita Włodarczyk (Polen) – Hammerwurf, Wiederholung ihres Erfolgs von 2012 Antoinette Nana Djimou Ida (Frankreich) – Siebenkampf, Wiederholung ihres Erfolgs von 2012
== Kritik == Kritisiert wurden die hohen Ticketpreise. Das Stadion Letzigrund war an keinem einzigen Tag ausverkauft, obwohl das Fassungsvermögen deutlich kleiner war als bei den vorangegangenen Europameisterschaften. Die täglichen Showacts nach Ende der Wettkämpfe wurden nur noch von wenigen Besuchern verfolgt.
In den Halbfinals (13. August) ausgeschieden:Julian Reus Deutschland GER – Lauf 1, Platz 4 in 10,35 sSven Knipphals Deutschland GER – Lauf 2, Platz 5 in 10,37 sPascal Mancini Schweiz SUI – Lauf 3, Platz 3 in 10,38 s In den Vorläufen (12. August) ausgeschieden:Reto Amaru Schenkel Schweiz SUI – Lauf 5, Platz 6 in 10,44 s
Sources: de.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.